Teva's MS Drug Nails Primary Endpoints -- and Then Some

Powers, Marie
December 2010
BioWorld Today;12/10/2010, Vol. 21 Issue 238, p1
The article reports on the result of the two-year Phase III ALLEGRO study of the oral laquinimod for relapsing-remitting multiple sclerosis (RRMS) developed by Teva Pharmaceuticals which demonstrated a significant reduction in annualized relapse rate compared to placebo. The drug, which Teva is being developed in partnership with Active Biotech, has achieved clinical endpoints including significant reduction in disability progression as measured by the Expanded Disability Severity Scale (EDSS). The implication of this EDSS endpoint is also noted.


Related Articles

  • Teva/Active Biotech: laquinimod clinical program moves on.  // PharmaWatch: Monthly Review;Jul2007, Vol. 6 Issue 7, p15 

    The article reports on the positive result of the test of laquinimod, an oral disease modifying treatment for multiple sclerosis. Phase III clinical trials are initiated by Teva and Swedish biotech partner Active Biotech AB. It is stated that laquinimod is expected to become the fifth oral...

  • Investigational Laquinimod Demonstrates Its Potential as a New Oral Treatment For RRMS.  // Biomedical Market Newsletter;10/24/2011, Vol. 21, p121 

    The article reports on the presentation of data from a study conducted by Teva Pharmaceutical Industries Ltd. and Active Biotech AB on the potential of laquinod in treating multiple sclerosis. The findings of the phase III study suggests the effectiveness of laquinimod in reducing annualized...

  • Teva and Active Biotech announce fast track status for multiple sclerosis drug.  // PharmaWatch: Biotechnology;Mar2009, Vol. 8 Issue 3, p12 

    The article reports on the announcement made by Teva Pharmaceutical Industries, a generic pharmaceutical company and Sweden-based pharmaceutical company Active Biotech on the fast track designation given by the Food and Drug Administration to the oral laquinimod in the U.S. It cites that oral...

  • Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis.  // Biomedical Market Newsletter;8/28/2012, Vol. 21, p1 

    The article informs that Teva Pharmaceutical Industries Ltd. and Active Biotech AB are to initiate a third Phase III study of laquinimod, following the written agreement reached with the U.S. Food & Drug Administration (FDA) on the Special Protocol Assessment (SPA). The third Phase III...

  • Teva to Initiate Third Phase III Trial of Oral Laquinimod for the Treatment of Relapsing Remitting Multiple Sclerosis.  // Biomedical Market Newsletter;8/15/2012, Vol. 21, p1 

    The article presents information on the clinical development program of once-daily oral laquinimod from Teva Pharmaceutical Industries Ltd. and Active Biotech AB for the treatment of relapsing-remitting multiple sclerosis (RRMS). The companies are going to start a third Phase III trial of...

  • Discontinuation of higher laquinimod doses in two MS trials.  // Reactions Weekly;1/16/2016, Vol. 1584 Issue 1, p1 

    An abstract is presented of the article "Teva and Active Biotech Announce Discontinuation of Higher Doses of Laquinimod in Two Multiple Sclerosis Trials" published on January 4, 2016 on the website www.tevapharm.com.

  • Mixed messages about Provigil for MS fatigue. Kraut, Rochelle // Inside MS;Feb/Mar2006, Vol. 24 Issue 1, p29 

    The article considers the therapeutic use of Progivil for individuals with multiple sclerosis (MS). Physicians began prescribing Progivil for MS fatigue. Since there were no serious side effects, it seemed safe to give it a try. However, a rigorous controlled trial, published in the April 2005...

  • Fingolimod finds favour in MS.  // PharmacoEconomics & Outcomes News;10/4/2008, Issue 563, p9 

    The article focuses on a phase II study, presented at the World Congress on Treatment and Research in Multiple Sclerosis, which showed that oral fingolimod may improve health-related (HR) quality of life (QOL) among patients with relapsing multiple sclerosis (MS). 281 patients who were...

  • Multiple sclerosis: Closing in on an oral treatment. Martin, Roland // Nature;3/18/2010, Vol. 464 Issue 7287, p360 

    The article discusses two clinical trials on the possibility of the drug fingolimod (FTY720) as an oral treatment for multiple sclerosis. The trials each involved 1,300 patients who were treated with either FTY720 or a placebo drug in the first trial, and either FTY720 or interferon-β in the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics